TCRT Earnings Alaunos Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Chart & overview → Latest filing
Annual results
EPS
Quarterly results
EPS
Reported EPS history
1–46 of 46
| Q2 2026 | 2026-06-30 | -0.41 | 2026-08-14 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.59 | 2026-05-15 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | -0.35 | 2026-03-31 | 10-K |
| FY 2025 | 2025-12-31 | -2.20 | 2026-03-31 | 10-K |
| Q3 2025 | 2025-09-30 | -0.55 | 2025-11-14 | 10-Q |
| Q2 2025 | 2025-06-30 | -0.63 | 2025-08-14 | 10-Q |
| Q1 2025 | 2025-03-31 | -0.67 | 2025-05-15 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | -0.46 | 2025-03-31 | 10-K |
| FY 2024 | 2024-12-31 | -2.92 | 2025-03-31 | 10-K |
| Q3 2024 | 2024-09-30 | -0.70 | 2024-11-14 | 10-Q |
| Q2 2024 | 2024-06-30 | -0.71 | 2024-08-14 | 10-Q |
| Q1 2024 | 2024-03-31 | -1.05 | 2024-05-15 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | -4.88 | 2024-04-01 | 10-K |
| FY 2023 | 2023-12-31 | -21.97 | 2024-04-01 | 10-K |
| Q3 2023 | 2023-09-30 | -5.30 | 2023-11-14 | 10-Q |
| Q2 2023 | 2023-06-30 | -5.49 | 2023-08-14 | 10-Q |
| Q1 2023 | 2023-03-31 | -6.30 | 2023-05-10 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | -5.10 | 2023-03-07 | 10-K |
| FY 2022 | 2022-12-31 | -26.10 | 2023-03-07 | 10-K |
| Q3 2022 | 2022-09-30 | -6.00 | 2022-11-14 | 10-Q |
| Q2 2022 | 2022-06-30 | -7.50 | 2022-08-15 | 10-Q |
| Q1 2022 | 2022-03-31 | -7.50 | — | — |
| FY 2021 | 2021-12-31 | -55.50 | — | — |
| Q3 2021 | 2021-09-30 | -16.50 | — | — |
| Q2 2021 | 2021-06-30 | -16.50 | — | — |
| Q4 2020 | 2020-12-31 | -16.50 | 2021-03-01 | 10-K |
| FY 2020 | 2020-12-31 | -57.00 | 2021-03-01 | 10-K |
| Q3 2020 | 2020-09-30 | -15.00 | — | — |
| Q2 2020 | 2020-06-30 | -13.50 | — | — |
| Q1 2020 | 2020-03-31 | -13.50 | — | — |
| Q4 2019 | 2019-12-31 | -13.50 | 2020-03-02 | 10-K |
| FY 2019 | 2019-12-31 | -105.00 | 2020-03-02 | 10-K |
| Q3 2019 | 2019-09-30 | -64.50 | — | — |
| Q2 2019 | 2019-06-30 | -13.50 | — | — |
| Q1 2019 | 2019-03-31 | -12.00 | — | — |
| Q4 2018 | 2018-12-31 | 193.50 | 2019-03-05 | 10-K |
| FY 2018 | 2018-12-31 | 144.00 | 2019-03-05 | 10-K |
| Q3 2018 | 2018-09-30 | -19.50 | — | — |
| Q2 2018 | 2018-06-30 | -18.00 | — | — |
| Q1 2018 | 2018-03-31 | -22.50 | — | — |
| FY 2017 | 2017-12-31 | -79.50 | — | — |
| FY 2016 | 2016-12-31 | -198.00 | — | — |
| Q3 2012 | 2012-09-30 | -34.50 | 2012-11-08 | 10-Q |
| Q3 2011 | 2011-09-30 | -1.50 | 2011-11-03 | 10-Q |
| Q3 2010 | 2010-09-30 | -39.00 | 2011-08-01 | 10-Q |
| Q3 2009 | 2009-09-30 | -19.50 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.